Patients (N = 8) | |
---|---|
Age, median (range), years | 55 (30–65) |
Histology, N (%) | |
Invasive ductal carcinoma | 6 (75%) |
Invasive lobular carcinoma | 1 (13%) |
Unknown | 1 (13%) |
Hormone receptor status, N (%) | |
ER+ and PR+ | 3 (38%) |
ER- and PR- | 5 (63%) |
HER2 expression, N (%) | |
IHC 0-2+ and/or FISH- | 3 (38%) |
IHC 2+ and FISH+, IHC3+ | 2 (25%) |
Triple negative, N (%) | |
Yes | 3 (38%) |
No | 5 (63%) |
ECOG performance status, N (%) | |
<2 | 0 (0%) |
2 | 4 (50%) |
3 | 4 (50%) |
Chemotherapy lines in metastatic setting, N (%) | |
0 | 1 (13%) |
1 | 2 (25%) |
2 | 2 (25%) |
≧3 | 3 (38%) |
Coexisting brain parenchymal metastasis, N (%) | |
Yes | 7 (88%) |
No | 1 (13%) |
Prior therapy for CNS metastasis, N (%) | |
Surgery | 2 (25%) |
Radiotherapy | 4 (50%) |
Numbers of metastatic sites, N (%) | |
Median (range) | 2 (1–4) |
1 | 2 (25%) |
2 | 4 (50%) |
3 | 1 (13%) |
4 | 1 (13%) |
Metastatic sites other than brain, N (%) | |
Lung | 3 (38%) |
Bone | 2 (25%) |
Liver | 1 (13%) |
Others | 4 (50%) |
Systemic disease not under control, N (%) | 5 (63%) |